ACMA Board of Governors
Accreditation Council for Medical Affairs
PhD, BCMAS President, Chief Executive Officer, Accreditation Council for Medical Affairs
Michael H. Davidson
MD, FACC, FNLA Chief Scientific Officer Corvidia Professor of Medicine Prtizker School of Medicine University of Chicago
MD, BCMAS, FACP Chief Medical Officer, Head of Global Medical Affairs Ipsen Biosciences Board of Directors A2A Pharmaceuticals
Founder, Managing General Partner JALAA Equities Board Member, Ligand Pharmaceuticals
Sharad (Bob) Chib
Executive MBA Head, Corporate Strategy, Innovation & Business Development Astellas Pharma
MBA Chairman, V ClinBio Board of Directors, Neurotez Inc. Board of Directors, Hyalo Technologies Former President, CEO Otsuka Pharmaceuticals
MD, MBA President & CEO, Accera, Inc.
MBA CEO & President, Member of the Board, ODH, Inc. (subsidiary of Otsuka America, Inc.)
Dr. William Soliman is a seasoned executive with several years of experience in the pharmaceutical and biotechnology industry. He has held several key positions where he was instrumental in launching a variety of innovative platforms expanding the role of medical affairs across the industry. He is often invited to speak at important pharmaceutical industry conferences focusing on medical affairs, patient navigation and its relationship to field based medical teams, and the ever-changing role of the medical science liaison (MSL). He has a wide range of experience holding a variety of critical management roles across the industry at companies such as Retrophin, Veeva Systems, Eisai, Gilead Sciences, Abbott Laboratories, Boehringer Ingelheim and Merck. Dr. Soliman previously also served as Vice President of Medical and Scientific Affairs at CME LLC, a leading provider of CME to healthcare providers nationwide.
He has published extensively and led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes and obesity, and has collaborated with some of the nation’s top research institutions such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program, and the University of Pennsylvania’s Center for Weight & Eating Disorders. Dr. Soliman was most recently invited to speak at the Center for Medical Technology & Policy’s (CMTP) conference on Comparative Effectiveness Research to help inform payers, healthcare policy makers, physicians and patients on the most effective ways to design clinical trials to better address gaps in medicine. He also presented at the 2014 annual American Diabetes Association (ADA) Conference on preventing the progression of type 2 diabetes among pre-diabetic overweight and obese individuals. Dr. Soliman has also held several academic appointments at Seton Hall University’s School of Health & Medical Sciences, New Jersey City University, Kean University’s College of Natural & Applied Sciences, and Touro Colleges of Osteopathic Medicine, Pharmacy & Physical Therapy, teaching a variety of courses, including clinical therapeutics, pharmacology, pathophysiology and epidemiology. Dr. Soliman earned his Ph.D., MPhil from Columbia University, his bachelor’s degree from New York University and his master’s degree from St. Peter’s University. Dr. Soliman has served as a board member for the MSL Institute. He is a member of several organizations including the American College of Cardiology (ACC), the American Diabetes Association (ADA), The Obesity Society (TOS), the American Association of Clinical Endocrinology (AACE), the American Society of Bariatric Physicians (ASBP), the American Heart Association (AHA), and the Drug Information Association (DIA), and he is a life sciences consultant board member at GLG consulting and the American Chemical Society (ACS).
MD, BCMAS, FACP
Dr. Sotirios Stergiopoulos is Senior Vice President and Head of Global Medical Affairs and a member of the R&D Leadership team at Ipsen BioScience. Sotirios has a extensive experience in directing medical affairs worldwide strategies and plans and a solid expertise in Oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumor indications. Sotirios’ past experience includes Vice President, Head of Global Medical Affairs Oncology at Baxalta (now Shire, Cambridge, MA), Executive Medical Director Oncology US Medical Affairs at Celgene Corporation (Summit, NJ), Senior Global Brand Medical Director Oncology at Novartis Pharmaceuticals (East Hanover, NJ) and Director Medical Affairs Oncology at Bayer Healthcare (Montville, NJ).
Dr. Stergiopoulos earned his M.D at the University of Medical Sciences of Poznan, Poland. He completed his residency in Internal Medicine at the Albert Einstein College of Medicine (NY), a clinical and research fellowship in Medical Genetics at Harvard Medical School and a research fellowship at National Institutes of Health where he had received an Intramural Research Training Award.
Dr. Stergiopoulos is currently an Attending Physician in the Department of Internal Medicine at
Jacobi Medical Center, Albert Einstein College of Medicine (NY). In addition, he holds a Masters in Biotechnology Enterprise and Entrepreneurship (MBEE) from The Johns Hopkins University (Baltimore, MD). Sotirios is a Fellow of the New York Academy of Medicine as well as the Royal Society of Medicine (UK). He also is a Member of the American Association of Cancer Research, American Society of Clinical Oncology, and sits on multiple Boards as well as Chairman of Board of A2A Pharmaceuticals, a fragment based computational drug design company.
Michael H. Davidson
MD, FACC, FNLA
Michael H. Davidson, MD, is Professor of Medicine and Director of Preventive Cardiology at the University of Chicago. Dr. Davidson earned his medical degree from The Ohio State University College of Medicine in Columbus. He then completed his residency and fellowship in cardiology at Rush University Medical Center in Chicago.
An active researcher, Dr. Davidson’s clinical research background encompasses both pharmaceutical and nutritional clinical trials. His extensive research on statins, novel lipid-lowering drugs, and nonpharmacologic risk factor reduction has established him as a key opinion leader in this area. A prolific author and lecturer on lipid disorders, nutrition, and atherosclerosis, Professor Davidson has coordinated more than 1,000 clinical trials in areas of preventive cardiology and published more than 250 articles for leading medical journals and has written 3 books on Lipidology.
Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology. He is a Fellow of the American College of Cardiology and the American College of Chest Physicians. In addition, he was President (2010-2011) of the National Lipid Association. Expertscape ranks Professor Davidson one of the top five lipid experts in the world; he has been named one of the The Best Doctors in America for the past 12 years and was named Father of the Year by the American Diabetes Association in 2010.
Jason Aryeh has more than twenty years of equity investment experience focused on the life sciences industry. He is the Founder and Managing General Partner of JALAA Equities, LP, a private investment fund focused on the biotechnology and medical device sectors. He has served in such capacity since 1997.
Mr. Aryeh serves on the Board of Directors of Ligand Pharmaceuticals and several other Boards. Additionally, he has served as Chairman of Ligand’s Nominating & Governance and on its Compensation Committee since H2 2006. Jason Aryeh has also served as Chairman, been on the Board of Directors, or served as a consultant, to many other public and private life sciences companies and charitable foundations, including the Cystic Fibrosis Foundation. Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics.
Sharad (Bob) Chib has more than twenty years of executive experience in the pharmaceutical and life sciences industries; both in US and international healthcare markets. Most recently he served as head of Corporate Strategy, Innovation, and Business Development at Astellas Pharma, where he led the overall strategic direction and growth plan of the Americas Operations. Previously he held various leadership roles across the organization, including the head of the Strategic Account Business Unit, an incubator that accelerated Astellas’ commercial model transformation. He also led the development of the Global Medical Affairs organization and the subsequent design and launch of Astellas’ Global Marketing Strategy function.
Before joining Astellas in 2005, Bob served in positions of increasing responsibility at various organizations, including TAP Pharmaceuticals. His career spans a variety of diverse disciplines, such as clinical research, sales, marketing, new product planning, managed markets, business development, corporate strategy and global commercial operations. Bob holds an Executive MBA from the Northwestern University Kellogg School of Management and a Bachelor of Science in Biological Studies from Rutgers University.
Bob managed a $6B P&L at Otsuka while managing a diverse and growing product portfolio across the cardio-renal, neuroscience, oncology, and medical device markets. Having compiled more than twenty five years of experience in the pharmaceutical industry, across commercial and general management roles for premium companies within the industry he was instrumental in building ABILIFY®, Abilify Maintena®, SAMSCA®, SPRYCEL® and Rexulti®. As Vice President and Global Business Manager for Oncology at Wyeth, he led the global launch of Torisel for RCC and later assumed responsibility for U.S. Commercial Operations.
Bob began his career in pharmaceuticals with Johnson & Johnson where he held positions of increasing responsibility. During his tenure at Otsuka, Bob held senior level executive roles including President & COO for North America and ultimately Bob was in the role of President & CEO of Otsuka America Pharmaceuticals, Inc. He previously held the position of Board Chairman for Otsuka Canada. More recently Bob served as CEO for V ClinBio, an early stage Biopharmaceutical Technology Platform. Bob is currently Executive Advisor and a member of the Board of Directors for Hyalo Technologies; as well as Executive Advisor for Cellix Bio Sciences, Inc. which recently merged with V ClinBio; additionally, he is a Board Member of Neurotez a Biotech startup focused on Alzheimer’s Disease. Previously, Bob served on the board of Immunomedics a publicly traded company focused on Oncology.
Bob holds a BA from Rutgers University and an MBA from the Haub School of Business at Saint Joseph’s University.
Dr. Stacey is President and CEO of Accera, a global clinical stage biotechnology company focused on the development of therapeutics for CNS disease. Prior to joining Accera, he was with Inventages, the Nestlé backed venture capital and private equity group, with $1.5Bn under management. There he led the CNS interest as well as the funds interest in Asia. Prior to Inventages, Dr. Stacey ran a medical device company and worked for a number of early stage healthcare companies.
Dr. Stacey has served globally on the Board of Directors of numerous life sciences companies and organizations including the Alzheimer’s Association Business Consortium.
Dr. Stacey received his medical degree from King’s College London and practiced as a trauma and reconstructive surgeon. His undergraduate degree and research were in the neurosciences at University of College London. Dr. Stacey also completed an MBA at the London Business School and the Wharton School.
Michael Jarjour is a senior health care executive with 20+ years of experience steering organizations to new heights of innovation and profitability. His extensive background in commercialization—and expertise in developing novel health care technologies and the vision, teams, infrastructures, and budgets to support them—has increased value in both “big pharma” and healthcare technology environments.
Working at the intersection of strategic vision and practical execution, Michael has delivered industry-changing technologies and achieved rapid, sustained growth. He recruits top talent, builds robust organizations, and facilitates all stages of commercialization to make a powerful impact on patients’ lives, improving health care delivery, accessibility, and outcomes.
Over the course of his career, Michael has broken new ground in novel health care technology (with digital technology, AI, machine learning at the forefront), revenue-generating commercialization (digital solutions as well as early-development and non-promoted, late-stage pharmaceutical products), and fundraising (to jumpstart and scale organizations). He attributes his success to the determination, expertise, and hard work of his teams, as well as an ability to monitor ever-emerging opportunities and key trends in health care innovation and respond accordingly.
Michael held key positions at Otsuka, Organon, Bristol-Myers Squibb, Pharmacia, Warner Lambert and Wyeth. He received his undergraduate degree in Finance from Florida International University and his MBA from Rutgers University.